Wegovy and Contrave are prescription weight-management medicines with different active ingredients, mechanisms and safety warnings. Wegovy contains semaglutide, a GLP-1 receptor agonist, while Contrave combines naltrexone and bupropion in an extended-release oral tablet. Contrave is not simply a branded version of bupropion used for depression or smoking cessation.
The relevant purchasing decision starts with the exact FDA-labeled treatment, not a general claim that one pill or injection is best. Wegovy spans approved oral and injectable formulations; Contrave has its own indication, contraindications, medication interactions and boxed warning related to suicidal thoughts and behaviors. Its naltrexone component also makes opioid use a crucial prescribing issue.
This comparison reviews differences useful before discussing legitimate U.S. pharmacy access. It does not recommend changing antidepressant treatment, using Contrave with opioids, or interpreting cross-trial weight-loss percentages as if the products were directly randomized against each other.
Wegovy semaglutide affects GLP-1 receptor pathways; Contrave combines opioid receptor antagonist naltrexone with antidepressant bupropion. Mechanism alone is insufficient to establish which is clinically appropriate.
A patient taking bupropion for a different reason has not thereby started an equivalent Contrave weight-management regimen. The combination’s approved dosing and warnings require their own review.
Contrave is an extended-release naltrexone/bupropion combination; Wegovy products contain semaglutide. Compare their actual labeled uses, contraindications and pharmacy identity. Contrave adds a boxed warning about suicidal thoughts and behaviors, serious seizure-related restrictions and opioid contraindications, so an “oral alternative” pitch cannot replace medication reconciliation.
Wegovy also has FDA-approved oral tablets, as well as weekly injections and the HD presentation. The contrast is not automatically pill versus pen. Neither product may be selected solely on a cross-trial weight-loss percentage: no direct comparative study is established here, and background therapies, populations and endpoints differ.
| Decision point | Wegovy | Contrave |
|---|---|---|
| Ingredients | Semaglutide | Naltrexone/bupropion ER |
| Mechanism | GLP-1 receptor agonism | Opioid antagonism and bupropion effects |
| Forms | Wegovy oral and injectable presentations | Extended-release oral tablets |
| Important safety distinction | GLP-1 boxed warning, other label risks | Suicidality boxed warning; seizure and opioid issues |
| Use context | Product-specific weight-management indications | Brand-specific chronic weight-management indication |
| Access | Valid prescription and licensed pharmacy | Valid prescription and licensed pharmacy |
Wegovy has both oral semaglutide tablets and multiple injection presentations, each with distinct labeling. Contrave is an extended-release oral combination tablet and has separate administration instructions.
A buyer seeking pills should compare the actual prescribed Wegovy tablet with Contrave, not treat every semaglutide product as injection-only. The Wegovy pill page explains the semaglutide oral product independently.
Contrave carries a boxed warning regarding suicidal thoughts and behaviors associated with antidepressant medications in some age groups, and it has significant contraindications including seizure disorders and chronic opioid use. Naltrexone can precipitate opioid withdrawal or block opioid effects.
These matters require active medication reconciliation and clinician review. Someone using opioids, including some pain or dependence treatments, should not infer Contrave suitability from retail advertising.
Wegovy products carry the boxed thyroid C-cell tumor warning and other GLP-1-related precautions. The presence of different warnings does not imply one medicine is universally safer.
Safety decisions include existing conditions, other medicines, age-specific labeling and tolerability. Combining products or switching treatment without prescriber assessment is not supported by a consumer comparison.
Reported weight-loss averages for separate Wegovy and Contrave trials reflect different populations, doses, counseling, durations and missing-data assumptions. Without a comparable randomized direct study, a one-number “winner” is misleading.
The buying context should be grounded in the actual FDA indications and the clinical evaluation, with costs and product access treated as independent practical factors.
The prescription should specify the exact brand, dosage form and quantity. Before checking coverage, the patient and prescriber should reconcile all current medicines, including opioids and other products containing bupropion.
A legitimate U.S. pharmacy requires a valid prescription and pharmacist access. Claims that Contrave can be recreated with arbitrary OTC supplements or that Wegovy is available without a prescription should not guide buyers.
Before considering Contrave, make a complete list of opioids (including some prescribed pain medicines and medicines for opioid-use disorder), other bupropion-containing drugs, seizure history, uncontrolled blood pressure, pregnancy potential and relevant mental-health history for the prescriber. Those issues are not interchangeable with Wegovy’s GLP-1 contraindications and precautions.
If the motivation is avoiding injections, consider that Wegovy has a separate FDA-approved oral tablet; its fasting routine may affect suitability. The Wegovy pill profile covers that product, while the Contrave clinician decision must address opioid exposure and the whole combination medication.
A person taking a bupropion-containing medication may assume Contrave is a straightforward add-on or that its existing prescription can be redirected. It is not; the approved naltrexone/bupropion combination carries additional contraindications and interaction concerns. Review the broader alternatives hub only after recognizing that ingredient overlap does not authorize co-use.
Insurance and prior authorization are also drug-specific. The semaglutide insurance guide explains why Wegovy coverage requires its own benefit verification; it does not establish the coverage or clinical appropriateness of Contrave.
Contrave combines two ingredients in one approved extended-release tablet. A prescription for bupropion alone is not the approved Contrave product, and a patient should not add naltrexone or change antidepressant treatment based on an affiliate comparison. The prescriber must evaluate the individual’s complete medication list and product-specific safety requirements.
Wegovy may be ordered as a distinct tablet or injection product with different administration and labeled populations. After a clinician selects a medicine, see Contrave dispensing or Wegovy pharmacy steps, not a single “weight-loss Rx” checkout.
For Contrave, ask the pharmacist to confirm that the dispensed item is the approved naltrexone/bupropion ER combination, that the prescription matches, and that interactions with the recorded medicines have been reviewed. A product offered as a substitute made from separate prescriptions should be referred back to the treating clinician.
For Wegovy, verify whether the order is for oral tablets, a standard pen or HD. All require lawful dispensing, but matching the exact semaglutide form is a different identification task from checking a combination-tablet label. An online referral platform is not necessarily the dispensing pharmacy.
Compare Contrave as a combination brand against the prescribed Wegovy presentation, using actual supply and current coverage criteria. A payer may classify the medicines differently or have distinct weight-management exclusions and prior-authorization processes. If either is not covered, obtain the plan’s written reason instead of assuming the alternative is automatically eligible.
For Wegovy pricing conditions, consult the branded formulation price guide. For Contrave, confirm current pharmacy or official program terms; do not equate the cost of separately purchased naltrexone and bupropion with the prescribed combination.
This is a buyer-oriented product comparison, not advice on antidepressants, opioid management or personal weight-loss treatment.
Some commercial links may generate compensation, which does not affect FDA labeling or clinical eligibility.
No. Contrave is a naltrexone/bupropion extended-release combination.
No. Wegovy contains semaglutide.
No. The approved combination contains naltrexone as well as bupropion and has specific labeling.
No. Opioid use is a key contraindication and interaction concern requiring clinician review.
Yes. Its label includes a warning about suicidal thoughts and behaviors.
Yes. Wegovy has FDA-approved oral tablets as well as injection products.
No universal result follows from separate clinical trials; suitability depends on the patient and product.
Yes. Both require valid U.S. prescriptions.
No. These are different drugs with separate prescriptions and labeling.